A Multicenter, Multi-Arm, Randomized, Multi-Dose, Placebo-Controlled, Double-Blind, Phase 3 Study of Intravesical Apaziquone (EOquin) as a Surgical Adjuvant in the Immediate Postoperative Period in Patients Undergoing TURBT

Trial Profile

A Multicenter, Multi-Arm, Randomized, Multi-Dose, Placebo-Controlled, Double-Blind, Phase 3 Study of Intravesical Apaziquone (EOquin) as a Surgical Adjuvant in the Immediate Postoperative Period in Patients Undergoing TURBT

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Dec 2016

At a glance

  • Drugs Apaziquone (Primary)
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Sponsors Spectrum Pharmaceuticals
  • Most Recent Events

    • 27 Sep 2016 Status changed from recruiting to active, no longer recruiting.
    • 26 Oct 2015 According to a Spectrum Pharmaceuticals media release, the first patient has been dosed in this trial.
    • 13 Oct 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top